Is Vericel Corporation (VCEL) a Buy, Sell, or Hold?
Vericel Corporation
NASDAQ:VCEL
$46.09 USD
-$1.4 (-2.95%)
- Volume
- 632.95K
- Average Volume
- 648.7K
- Market Capitalization
- $2.35B
- P/E Ratio
- 107.44
- Dividend Yield
- 0.00%
- Price Target
- $46.00
- Year High
- $48.33
- Year Low
- $28.95
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.18
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Dominick C. Colangelo |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | VCEL |
| CUSIP | 92346J108 |
| CIK | 0000887359 |
| Web | https://vcel.com |
| Phone | 617 588 5555 |
| Currency | USD |
| Employees | 398 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.27 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.18 |
| Quick Ratio | 4.79 |
| Cash Ratio | 2.32 |
Sales & Book Value
| Annual Sales | $276.26M |
| Price / Sales | 8.06 |
| Cash Flow | 1.14 |
| Price / Cash Flow | 40.72 |
| Price / Book | 6.57 |
Price Target and Rating
| Average Stock Price Forecast | $46.00 |
| High Stock Price Forecast | $70.00 |
| Low Stock Price Forecast | $42.00 |
| Forecast Upside/Downside | 0.20% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $0.32 |
| Trailing P/E Ratio | 107.44 |
| PEG Ratio | 0.16 |
| P/E Growth | 0.16 |
| Net Income | $16.52M |
| Net Margin | 7.35% |
| Pretax Margin | 7.64% |
| Return on Equity | 6.41% |
| Return on Assets | 4.42% |
Financials Score
| AltmanZ Score | 11.37 |
| Piotroski Score | 7.00 |
| Working Capital | 196.91M |
| Total Assets | 485.63M |
| Ebit | 22.96M |
| Market Cap | 2.42B |
| Total Liabilities | 129.4M |
Poll Results
About Vericel Corporation (NASDAQ:VCEL) Stock
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thick ... ness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests
2026-06-27 12:58:26
10,000 Common Stock shares were sold for a transaction value of $402,000 at an average price of around $40.24 per share on June 18, 2026. The sale represented 38% of Halpin's direct Common Stock holdings, reducing his direct stake from 26,248 to 16,248 shares, though he also has options.
Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026
2026-06-09 08:30:00
BURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16th, 2026.
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More
2026-05-30 14:39:34
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.
Vericel Q1 Earnings Call Highlights
2026-05-09 02:10:08
Vericel NASDAQ: VCEL reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected NexoBrid procurement revenue from a new federal contract.
Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript
2026-05-07 23:31:13
Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript
Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates
2026-05-07 12:16:20
Vericel Corporation (VCEL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.
Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
2026-05-07 07:45:00
Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91%
Wall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a Bet
2026-05-04 10:56:10
The average of price targets set by Wall Street analysts indicates a potential upside of 53.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Frequently Asked Questions
-
What is the current Vericel Corporation (VCEL) stock price?
-
Vericel Corporation(NASDAQ:VCEL) stock price is $46.09 in the last trading session. During the trading session, VCEL stock reached the peak price of $48.33 while $28.95 was the lowest point it dropped to. The percentage change in VCEL stock occurred in the recent session was --2.95% while the dollar amount for the price change in VCEL stock was -$-1.4.
-
VCEL's industry and sector of operation?
-
The NASDAQ listed VCEL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of VCEL?
-
Jonathan Hopper FRCSEd. | Chief Medical Officer
Dominick C. Colangelo | Chief Executive Officer, President & Director
Eric Burns | Vice President of Finance & Investor Relations
Jonathan Siegal | Principal Accounting Officer, Vice President & Corporate Controller
Joseph Anthony Mara Jr. | Chief Financial Officer & Treasurer -
How many employees does VCEL have?
-
Number of VCEL employees currently stands at 398. VCEL operates from 64 Sidney Street, Cambridge, MA 02139, US.
-
Link for VCEL official website?
-
Official Website of VCEL is: https://vcel.com
-
How do I contact VCEL?
-
VCEL could be contacted at phone #617 588 5555 and can also be accessed through its website. VCEL operates from 64 Sidney Street, Cambridge, MA 02139, US.
-
How many shares of VCEL are traded daily?
-
The average number of VCEL shares traded daily for last 3 months was 648.7K.
-
What is the market cap of VCEL currently?
-
The market value of VCEL currently stands at $2.35B with its latest stock price at $46.09